Boithuto ba tleliniki bo etselitsoe ho lekola polokeho le katleho ea LNK01001 ho batho ba nang le ramatiki ea ramatiki e itekanetseng ho isa ho e matla ba nang le karabelo e mpe kapa ho se mamelle lithethefatsi tse tloaelehileng tsa maiketsetso tse fetolang li-antirheumatic drugs (csDMARDs).
LNK01001 ke lithethefatsi tsa pele tse ncha tse entsoeng ke Lynk Pharmaceuticals, 'me ke "kinase inhibitor" e khethiloeng bakeng sa phekolo ea mafu a autoimmune. Nakong e fetileng, LNK01001 e phethetse lithuto tsa bongaka tsa Mokhahlelo oa Pele lithutong tse phetseng hantle lehlabuleng la selemo sena Chaena le Australia le Japane, li tšehelitsoe ke Lynk Pharmaceuticals le molekane oa eona oa US, ka ho latellana. Liphetho li bontšitse hore moriana o bolokehile ebile o mamelloa hantle. Ho phaella moo, LNK01001 e ile ea amoheloa ke Tsamaiso ea Sechaba ea Lihlahisoa tsa Bongaka ea Chaena (NMPA) bakeng sa tlhahlobo ea kliniki ea matšoao a macha - ankylosing spondylitis (AS) le atopic dermatitis (AD).
Moprofesa Xiaofeng Zeng ke mofuputsi ea ka sehloohong oa phuputso ena le mookameli oa Lefapha la Rheumatology le Immunology ea Peking Union Medical College Hospital le Chinese Academy of Medical Sciences.
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- Nakong e fetileng, LNK01001 e phethetse lithuto tsa bongaka tsa Phase I lithutong tsa bophelo bo botle lehlabuleng la selemo sena Chaena le Australia le Japane, li tšehelitsoe ke Lynk Pharmaceuticals le molekane oa eona oa US, ka ho latellana.
- Moprofesa Xiaofeng Zeng ke mofuputsi ea ka sehloohong oa phuputso ena le mookameli oa Lefapha la Rheumatology le Immunology ea Peking Union Medical College Hospital le Chinese Academy of Medical Sciences.
- Boithuto ba tleliniki bo etselitsoe ho lekola polokeho le katleho ea LNK01001 ho batho ba nang le ramatiki ea ramatiki e itekanetseng ho isa ho e matla ba nang le karabelo e mpe kapa ho se mamelle lithethefatsi tse tloaelehileng tsa maiketsetso tse fetolang li-antirheumatic drugs (csDMARDs).
